Biomea Fusion Inc
NASDAQ:BMEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shandong Jinling Mining Co Ltd
SZSE:000655
|
CN |
Biomea Fusion Inc
Long-Term Investments
Biomea Fusion Inc
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Investments
$268m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Investments
$3B
|
CAGR 3-Years
34%
|
CAGR 5-Years
43%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Investments
$5.7B
|
CAGR 3-Years
287%
|
CAGR 5-Years
207%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Investments
$10.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
32%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
